Roche Strikes $5.3B Deal with Zealand Pharma to Expand in Obesity Market
- Mar 12, 2025
- 1 min read
Basel, Switzerland, March 12, 2025 (Reuters) -- Roche has acquired rights to Zealand Pharma’s obesity drug petrelintide in a deal worth up to $5.3 billion. The agreement includes a $1.65 billion upfront payment and milestone-based incentives. This positions Roche to compete more aggressively in the booming weight-loss market.
Read full article here.
Comments